A phase 2 randomized, double-blinded, controlled study of ONT-380 vs. placebo in combination with capecitabine (C) and trastuzumab (T) in patients with pretreated HER2+ unresectable locally advanced or metastatic breast carcinoma (MBC).
Curigliano, G Loibl, S Müller, V Pivot, X Cameron, D
Curigliano, G
Loibl, S
Müller, V
Pivot, X
Cameron, D
Citations
Altmetric:
Abstract
Description
Date
2016-10-01
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
A phase 2 randomized, double-blinded, controlled study of ONT-380 vs. placebo in combination with capecitabine (C) and trastuzumab (T) in patients with pretreated HER2+ unresectable locally advanced or metastatic breast carcinoma (MBC). 2016, 27(suppl 6):312TiP Annals of Oncology